Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Up 7.71%
As of Friday, August 21, Rani Therapeutics Holdings, Inc.’s RANI share price has surged by 7.71%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. RANI
$0.87
0.01
1.54%
September 4, 2026 4:00:00 PM
EST
Volume: 380,748
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai’s Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Commentary & Analysis
Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Up 8.24%
As of Tuesday, August 18, Rani Therapeutics Holdings, Inc.’s RANI share price has surged by 8.24%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Up 5.94%
As of Tuesday, August 04, Rani Therapeutics Holdings, Inc.’s RANI share price has surged by 5.94%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Down 7.00%
As of Monday, July 27, Rani Therapeutics Holdings, Inc.’s RANI share price has dipped by 7.00%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Rani Therapeutics Holdings, Inc.’s (RANI) Stock Is Up 5.03%
As of Friday, July 24, Rani Therapeutics Holdings, Inc.’s RANI share price has surged by 5.03%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | RANI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $98.4 | $671.5 | 21% |
|
| Shares Out (Mil) | 187.2 | 43.5 | 75% |
|
| Institutional Ownership | 90.2% | 84.6% | 58% |
|
| Float (Mil) | 83.5 | 47.3 | 57% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 554 | 293 | 61% |
|
| Price Change (52-week) |
75.6% | 69.4% | 88% |
|
| Growth | RANI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 26.2% | 6.7% | 87% |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (28.9%) | (15.0%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.047) | ($0.173) | ($0.190) | |
| Month Ago EPS | ($0.050) | ($0.183) | ($0.213) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.053) | ($0.193) | ($0.220) | |
| Year/Year Chg | 20.5% | (61.5%) | (65.0%) | |
| Financials | RANI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $317 | 6% |
|
| Net Income (TTM) (Mil) | ($30) | ($11) | 21% |
|
| EPS (TTM) | ($0.217) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $5 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | na | $536 | na |
|
| Valuation | RANI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.43 | 2.81 | 57% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RANI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 68.1% | 96% |
|
| Net Margin | (618.0%) | (1.4%) | 1% |
|
| ROA | (77.5%) | (24.1%) | 8% |
|
| ROE | (179.1%) | (21.0%) | 5% |
|
| Liabilities to Assets | 21.1% | 32.3% | 14% |
|
| F-Score | 3 | 3 | 18% |
|
Rani Therapeutics Holdings, Inc. did not pass any screens on 9/3/2026.
